Lundi, 26 Octobre 2020
Dernières nouvelles
Principale » Analyzing with technical analysis: Eagle Pharmaceuticals, Inc. (EGRX), A. Schulman, Inc. (SHLM)

Analyzing with technical analysis: Eagle Pharmaceuticals, Inc. (EGRX), A. Schulman, Inc. (SHLM)

27 Juillet 2017

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings data on Monday, May 8th. National Planning Corp acquired 4,141 shares as Consolidated Edison Inc (ED)'s stock rose 9.35%. The Three Bays Capital Lp holds 1.22M shares with $68.68 million value, up from 367,346 last quarter. FMR LLC acquired a new position in shares of Eagle Pharmaceuticals during the fourth quarter valued at about $7,300,000. Thrivent Financial for Lutherans now owns 4,200 shares of the specialty pharmaceutical company's stock valued at $333,000 after buying an additional 60 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in Eagle Pharmaceuticals by 3.1% in the first quarter. Municipal Employees Retirement System of MI now owns 1,910 shares of the specialty pharmaceutical company's stock valued at $151,000 after buying an additional 120 shares during the last quarter. Comerica Bank increased its stake in shares of Eagle Pharmaceuticals by 5.2% in the fourth quarter. Eagle Pharmaceuticals has a 12 month low of $42.33 and a 12 month high of $97.15.

Among 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 3 have Buy rating, 1 Sell and 0 Hold. The company has market cap of $1.07 billion.

Further back, their 200-Day Simple Moving Average is -7.55% difference from today's price. Accern also gave headlines about the specialty pharmaceutical company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. Eagle Pharmaceuticals had a net margin of 44.48% and a return on equity of 79.25%. The firm had revenue of $76.80 million for the quarter, compared to analysts' expectations of $70.10 million. During the same period in the previous year, the company earned ($0.06) EPS. BNP Paribas Arbitrage SA now owns 1,548 shares of the specialty pharmaceutical company's stock valued at $128,000 after buying an additional 202 shares during the last quarter. On average, equities analysts anticipate that Eagle Pharmaceuticals will post $3.66 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another website, it was stolen and reposted in violation of worldwide trademark & copyright laws. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/07/27/wellington-management-group-llp-acquires-shares-of-4897-eagle-pharmaceuticals-inc-egrx.html. According to Thomson Reuters, sell-side analysts are forecasting a harmony target price of $21.85 on company shares. Piper Jaffray Companies set a $118.00 target price on shares of Eagle Pharmaceuticals and gave the company an "overweight" rating in a research report on Tuesday, May 9th. Zacks Investment Research raised Eagle Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Tuesday, May 2nd.

People made from alien atoms from a galaxy far, far away
The study, which required the equivalent of several million hours of continuous computing is published by Monthly Notices of the Royal Astronomical Society .

12/09/2015 - Eagle Pharmaceuticals Inc had its "buy" rating reiterated by analysts at William Blair.

Based on the latest notes released to investors, 1 analyst has issued a rating of "buy", 2 analysts "outperform", 0 analysts "hold", 1 analysts "underperform" and 0 analysts "sell". Analysts have placed a $91.75 price target on Eagle Pharmaceuticals, Inc., suggesting a 26.03% gain from recent close.

In related news, CFO Pete A. Meyers purchased 350 shares of the business's stock in a transaction dated Monday, June 12th. The stock was bought at an average cost of $71.49 per share, for a total transaction of $25,021.50. Following the completion of the transaction, the chief financial officer now directly owns 350 shares of the company's stock, valued at $25,021.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. (EGRX) stock price has gone down by -10.15% over the last 20 trading days, and its price is -25.06% below the 52-week high.

Eagle Pharmaceuticals, Inc.'s RSI is 35.17.